Business Wire

Headspace Health Announces Acquisition of AI-Driven Mental Health and Wellness Company, Sayana

12.1.2022 16:50:00 EET | Business Wire | Press release

Share

Headspace Health, the provider of the world’s most accessible, comprehensive digital mental health platform, today announced the acquisition of Sayana, an AI-driven mental health and wellness company. Sayana will expand Headspace Health’s ability to provide personalized self-care content to its growing global member base.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220112005244/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Headspace Health announces acquisition of AI-driven mental health and wellness company, Sayana.

Founded in 2018 and backed by Y Combinator in 2020, Sayana has supported users around the world to improve their mental wellness by helping its members become more mindful of the connections between their feelings and events. The Sayana Self-Care app leverages chat-based sessions with an AI persona named Sayana, who encourages users to track their mood along with what influences it. Sayana personalizes users’ experiences based on their check-ins and mood trends, surfacing high-quality content and self-care exercises rooted in cognitive behavioral therapy (CBT), acceptance commitment therapy (ACT) and dialectical behavioral therapy (DBT), as well as breathing exercises. In addition, the Sayana Sleep app helps members to enjoy deep and restful sleep sessions sequenced based on their mood and sleep patterns.

“Amidst a rapidly growing landscape of mental health and wellness apps, Sayana has developed a uniquely engaging member experience backed by world-class AI and machine learning algorithms,” said Russell Glass, CEO, Headspace Health. “Sayana's technology, and most importantly, Sayana’s team, will help us meaningfully advance our product and content strategy as we continue to build the world’s most comprehensive mental health and wellbeing platform.”

On the heels of its recent merger between Headspace and Ginger, Headspace Health is creating an integrated experience to tackle the full spectrum of mental health needs - from prevention to clinical care - all from one platform backed by AI and data science. Today, Ginger leverages AI to support its team of behavioral health coaches, therapists and psychiatrists to ensure quality interactions with members, comprehensive tracking of services, and close collaboration among care providers. Headspace harnesses the power of AI to surface and recommend content in order to foster healthy habit formation. With the addition of Sayana, Headspace Health will advance its capability to personalize member experiences - to better understand, support and improve their feelings and mood.

Sayana founder and CEO Sergey Fayfer will join Headspace Health and take on a product leadership role, along with an experienced team of engineers and designers who will further advance the company’s unique and engaging member experiences.

“Since our inception, we’ve been on a mission at Sayana to put self-care in everyone’s pocket,” said Sergey Fayfer, Founder and CEO of Sayana. “We’re thrilled to bring together our technology, engineering and design expertise to help advance Headspace Health’s efforts to democratize high-quality, affordable mental healthcare around the world.”

The terms of the deal were not disclosed.

About Headspace Health

Headspace Health is the world’s leading provider of mental health and wellbeing solutions. Through our flagship Headspace brand, we’ve touched the lives of over 100 million people in 190 countries through mindfulness tools for managing stress, sleep, and focus. Our enterprise brands, Headspace for Work and Ginger, are distributed through over 3,500 enterprises, including Starbucks, Adobe, Delta Air Lines, and ViacomCBS; and through health plans such as Cigna. Our members and enterprise partners’ employees have access to mindfulness and meditation tools, CBT, coaching, therapy, and psychiatry, ultimately helping them to be healthier and more productive. To learn more about Headspace Health and our family of brands, visit www.headspacehealth.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Victoria Barnes
Sr. Director, Global Communications & Corporate Marketing, Headspace Health
781 249 3738
press@headspacehealth.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 202619.10.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from across its rapidly progressing solid tumor portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 on October 23-27 in Madrid. Presentations will highlight an accelerating pipeline of differentiated targeted therapies, alongside a broad body of evidence for TEVIMBRA® (tislelizumab), including a late-breaking rapid oral presentation on TEVIMBRA in combination with ZIIHERA® (zanidatamab) in HER2+ gastroesophageal adenocarcinoma (GEA). Priority pipeline data include an oral proffered paper presentation on BeOne’s GPC3x4-1BB bispecific antibody, currently being studied in hepatocellular carcinoma (HCC) and first-in-human data for two investigational lung cancer assets, a CEA targeting antibody-drug conjugate (ADC), in CEA-expressing non-small cell lung cancer (NSCLC), and a brain-penetrant PRMT5 inhibitor in MTAP-deleted tumors, inclu

The Data Center Marketplace Is Booming, Inaugural Data Center World Europe Unites Data Center and Energy Decision-Makers and Experts in Vienna19.10.2026 13:00:00 EEST | Press release

Last week, Data Center World Europe, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators over three days at VIECON – Vienna Congress & Convention Center in Vienna, Austria. It was co-located with the leading global network infrastructure event Network X, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators. Tara Gibb, Senior Director, Data Center World Europe said, “The conference tackled the industry’s most urgent challenge: transforming Europe's data centre energy landscape. We brought together leaders from across the data ce

First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO ® (vedolizumab) Prolongs Time to First Disease-Related Complication19.10.2026 12:30:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) announced new data from VERDICT (NCT04259138), showing that treating adults with intravenous ENTYVIO® (vedolizumab) to achieve corticosteroid-free (CSF) disease clearance versus CSF symptomatic remission alone, resulted in a significantly longer time to first ulcerative colitis (UC)-related complication (hazard ratio 0.33 [95% confidence interval 0.17-0.67]; P=0.0014), reducing UC complication risk by nearly 70 percent. VERDICT, a Phase 4 ENTYVIO clinical trial, provides the first prospective, randomized evidence that disease clearance is an achievable and clinically relevant target in the treatment of moderate to severe ulcerative colitis.1 Results were presented during late-breaker and poster sessions at United European Gastroenterology (UEG) Week 2026 and published in the United European Gastroenterology Journal. “There has been increasing conversation about whether achieving deeper levels of remission – addressing both visible and microscopic inflammation

Boomi Acquires Elementary Data to Bring Trusted, Governed Data to the AI Era19.10.2026 12:00:00 EEST | Press release

Boomi, the data activation company for AI, today announced it has acquired Elementary Data, a provider of the widely adopted data observability solution that powers every workflow and AI agent with reliable data. Following Lunar.dev, Elementary is Boomi’s latest acquisition, strengthening the Boomi Enterprise Platform with the observability, quality, governance, and discovery capabilities enterprises need to deliver trusted data for AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261019376249/en/ Boomi Acquires Elementary Data to Bring Trusted, Governed Data to the AI Era Key Takeaways What Boomi acquired. Elementary provides unified observability, quality, governance, and discovery. Founded in 2022, Elementary began as an open-source project — now adopted by 1,500+ data teams, with 1.1M + monthly downloads, and a ~4,000-member community. In 2024, it launched Elementary Cloud which added enterprise-grade capabilities on t

Reply Earns “NVIDIA Physical AI Specialization” for Production-Ready Robotics and Digital Twins19.10.2026 11:00:00 EEST | Press release

Reply [EXM, STAR: REY] is among the first NVIDIA partners in the world to achieve the “Physical AI Specialization” within the NVIDIA Partner Network (NPN), in recognition of its expertise in developing and deploying AI-driven robotics and digital twin solutions for real-world operating environments. The specialization was awarded following a technical assessment covering a customer implementation, solution architecture, certified OpenUSD expertise and Reply’s development roadmap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261019881053/en/ Reply is among the first NVIDIA partners in the world to achieve the “Physical AI Specialization” within the NVIDIA Partner Network (NPN), in recognition of its expertise in developing and deploying AI-driven robotics and digital twin solutions for real-world operating environments. Physical AI is becoming increasingly relevant in manufacturing, warehousing and logistics as companies mo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye